TERAPI4.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: Technology NT60 (Q2867071): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: co-financing rate (P837): 76.0 percent, Removing co-finance rate from projects in portugal) |
(Removed claim: budget (P474): 25,000.0 euro) |
||||||
| Property / budget | |||||||
| |||||||
| Property / budget: 25,000.0 Euro / rank | |||||||
Revision as of 13:38, 21 October 2021
Project Q2867071 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | TERAPI4.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: Technology NT60 |
Project Q2867071 in Portugal |
Statements
1 April 2020
0 references
1 April 2023
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
40°12'40.28"N, 8°25'46.06"W
0 references
O projeto TERAPI4 visa a proteção dos direitos de Propriedade Intelectual de uma nova classe de agentes terapêuticos contra doenças amiloides raras de transtirretina. Estes novos compostos são pequenas moléculas pertencentes à série química NT60 desenvolvida pela BSIM Therapeutics. (Portuguese)
0 references
The TERAPI4 project aims to protect the intellectual property rights of a new class of therapeutic agents against rare amyloid transthyretin diseases. These new compounds are small molecules belonging to the NT60 chemical series developed by BSIM Therapeutics. (English)
7 July 2021
0 references
Coimbra
0 references
Identifiers
CENTRO-01-0247-FEDER-046897
0 references